INVESTIGATORS

Michelle O'Donoghue, MD, MPHMichelle O'Donoghue, MD, MPH is an Associate Physician in the Cardiovascular Division of Brigham and Women's Hospital and an Affiliate Physician in the Cardiovascular Division of Massachusetts General Hospital. She has been working as an investigator with the TIMI Study Group since 2005.

Dr. O'Donoghue's primary research focus is the design and conduct of multicenter clinical trials for patients with stable and unstable heart disease. She served as the co-Principal Investigator of the global SOLID-TIMI 52 trial, the phase III randomized trial of the direct Lp-PLA2 inhibitor darapladib in patients after an acute coronary syndrome. She is also served as the National Lead Investigator for the LATITUDE-TIMI 60 trial, the phase III randomized trial of losmapimod in ACS patients. Prior trial leadership includes the PRINCIPLE-TIMI 44 trial (a pharmacodynamic study of prasugrel versus clopidogrel in PCI) and the LANCELOT phase II program of the PAR-1 antagonist atopaxar. She is the local Principal Investigator of the PEGASUS-TIMI 54 trial (ticagrelor in patients with a history of myocardial infarction) and the CAMELLIA-TIMI 61 trial (lorcaserin in overweight patients with cardiovascular disease or risk factors). Additional clinical research interests include the evaluation of novel antiplatelet drugs, established and novel biomarkers, the study of women and heart disease and the development of novel therapeutics in the management of acute coronary syndromes.

Dr. O'Donoghue earned her medical degree from Columbia University College of Physicians and Surgeons in New York. She completed her residency in internal medicine and fellowship in cardiovascular medicine at Massachusetts General Hospital. She subsequently completed a Masters in Public Health degree at the Harvard School of Public Health.

Christian T. Ruff, MD, MPHChristian T. Ruff, MD, MPH is an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital and an Assistant Professor of Medicine at Harvard Medical School. Dr. Ruff graduated from Harvard University, earned his medical degree at Johns Hopkins University School of Medicine, and his masters of public health from the Harvard School of Public Health. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women’s Hospital. Dr. Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group and serves the Director of the Genetics Core Laboratory and the Co-Chairman of the Clinical Events Committee. He has led a broad array of projects, ranging from investigator initiated studies of biomarkers and genetic variants to large clinical trials. Dr. Ruff has investigated the efficacy of safety of antithrombotic therapies across the spectrum of cardiovascular disease, with a focus on stroke prevention in atrial fibrillation. Dr. Ruff has served on international antithrombotic guideline committees and has been invited to give hundreds of lectures nationally and internationally. He has authored many scholarly articles, editorials, reviews, and book chapters that include the New England Journal of Medicine, Lancet, Journal of the American Medical Association, American Journal of Medicine, Circulation, Journal of the American College of Cardiology, and Nature Reviews Cardiology.

Marc P. Bonaca, MD, MPHMarc P. Bonaca, MD, MPH is an Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital, an Assistant Professor of Medicine at Harvard Medical School and an investigator at the TIMI Study Group. Dr. Bonaca earned his medical degree (M.D.) from University of Connecticut School of Medicine and a Master of Public Health (M.P.H.) from the Harvard School of Public Health. He completed his internal medicine residency, fellowship in cardiovascular medicine and fellowship in vascular medicine at Brigham and Women's Hospital and is board certified in internal medicine and cardiology.

Dr. Bonaca's research interests include characterization and prediction of cardiovascular risk in patients with atherosclerotic vascular disease as well as investigation of therapies to reduce that risk. Specific disease states of interest include peripheral artery disease, stable coronary artery disease, and aortic disease. He is an active investigator in clinical trials investigating novel therapies including antithrombotic agents for the reduction of cardiovascular risk in patients with symptomatic peripheral artery disease and stable coronary disease. In addition, he is actively involved in the evaluation of established and novel biomarkers as well as clinical characteristics for risk prediction in specific patient populations. In addition to scientific investigation and clinical trial work, Dr. Bonaca leads the TIMI Safety Desk which includes 20 staff members and which is responsible for the monitoring and processing of safety data for multiple large international clinical trials.

In addition to his scientific, clinical trial, and safety responsibilities, Dr. Bonaca is an active member of the clinical staff at Brigham and Women's hospital and attends on the inpatient cardiology and cardiology/vascular medicine consult services. He maintains a regular clinic and is the Medical Director of the the Brigham and Women's Aortic Center.

Erin Bohula May, MD, DPhilErin Bohula May, MD, DPhil is an Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital, an Instructor of Medicine at Harvard Medical School, and an Investigator at the TIMI Study Group. Dr. Bohula May earned her Doctor of Philosophy (D.Phil.) in Molecular Biology from Oxford University on a Rhodes Scholarship and her medical degree (M.D.) from Harvard Medical School. She completed her internal medicine residency and fellowships in cardiovascular medicine and critical care medicine at Brigham and Women's Hospital. She is board certified in internal medicine, cardiology, and critical care medicine. 

Dr. Bohula May's research interests include the interplay of obesity, metabolic health and cardiovascular disease, evaluation of novel biomarkers and the application of innovative technologies for critically-ill cardiovascular patients. To this end, she is an investigator in a clinical trial studying the cardiovascular and metabolic impact of pharmacologic therapy for weight loss in obese or overweight individuals. In addition, she is investigating the prognostic utility of established and novel biomarkers for prediction of future cardiovascular events in multiple patient populations, including those with risk factors, stable vascular disease and acute coronary syndromes. Finally, she is studying novel, non-invasive methods of identifying and monitoring cardiogenic shock in the intensive care setting.

In addition to her scientific and trial responsibilities, Dr. Bohula May is an active member of the clinical staff at Brigham and Women's hospital and attends in the Cardiology Critical Care Unit and inpatient General Cardiology Service.

Back to top